General Information of Drug (ID: DM0QV1J)

Drug Name
Baclofen
Synonyms
Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA; ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Fragile X syndrome LD55 Phase 3 [2]
Therapeutic Class
Muscle Relaxants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 213.66
Logarithm of the Partition Coefficient (xlogp) -1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The sytemic clearance of drug is 180 mL/min []
Elimination
Seventy to eighty (70 - 80%) of a dose is measured in the urine as unchanged drug []
Half-life
The concentration or amount of drug in body reduced by one-half in 5.5 hours []
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.22468 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.69% [6]
Vd
The volume of distribution (Vd) of drug is 59 L []
Water Solubility
The ability of drug to dissolve in water is measured as 2.1 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Drug ineffective Not Available ADORA1 OTI7X39E [7]
Chemical Identifiers
Formula
C10H12ClNO2
IUPAC Name
4-amino-3-(4-chlorophenyl)butanoic acid
Canonical SMILES
C1=CC(=CC=C1C(CC(=O)O)CN)Cl
InChI
InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
InChIKey
KPYSYYIEGFHWSV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2284
ChEBI ID
CHEBI:2972
CAS Number
1134-47-0
DrugBank ID
DB00181
TTD ID
D01AJY
VARIDT ID
DR00858
ACDINA ID
D00057
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-aminobutyric acid B receptor (GABBR) TTDCVZW GABR1_HUMAN ; GABR2_HUMAN Modulator [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Drug Response [7]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Regulation of Drug Effects [9]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Protein Interaction/Cellular Processes [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Baclofen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Baclofen and Oliceridine. Acute pain [MG31] [11]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Baclofen and Dihydrocodeine. Chronic pain [MG30] [12]
Morphine DMRMS0L Major Additive CNS depression effects by the combination of Baclofen and Morphine. Chronic pain [MG30] [11]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Baclofen and Olopatadine. Conjunctiva disorder [9A60] [13]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Baclofen and Alfentanil. Corneal disease [9A76-9A78] [11]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Baclofen and Remifentanil. Corneal disease [9A76-9A78] [11]
Methadone DMTW6IU Major Additive CNS depression effects by the combination of Baclofen and Methadone. Cough [MD12] [11]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Baclofen and Ethanol. Cystitis [GC00] [13]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Baclofen and Brimonidine. Glaucoma [9C61] [14]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Baclofen and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [15]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Baclofen and Lasmiditan. Migraine [8A80] [16]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Baclofen and Flibanserin. Mood disorder [6A60-6E23] [17]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Baclofen and Thalidomide. Multiple myeloma [2A83] [18]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Baclofen and Levomethadyl Acetate. Opioid use disorder [6C43] [12]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Baclofen and Apraclonidine. Optic nerve disorder [9C40] [14]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Baclofen and Pentazocine. Pain [MG30-MG3Z] [11]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Baclofen and Dextropropoxyphene. Pain [MG30-MG3Z] [19]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Baclofen and Butorphanol. Pain [MG30-MG3Z] [11]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Baclofen and Oxymorphone. Pain [MG30-MG3Z] [11]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Baclofen and Levorphanol. Pain [MG30-MG3Z] [11]
Hydromorphone DMHP21E Major Additive CNS depression effects by the combination of Baclofen and Hydromorphone. Pain [MG30-MG3Z] [11]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Baclofen and Dezocine. Pain [MG30-MG3Z] [11]
Codeine DMJX6ZG Major Additive CNS depression effects by the combination of Baclofen and Codeine. Pain [MG30-MG3Z] [11]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Baclofen and Nalbuphine. Pain [MG30-MG3Z] [11]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Baclofen and Buprenorphine. Pain [MG30-MG3Z] [20]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Baclofen and Hydrocodone. Pain [MG30-MG3Z] [11]
Tramadol DMRQD04 Major Additive CNS depression effects by the combination of Baclofen and Tramadol. Pain [MG30-MG3Z] [11]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Baclofen and Meperidine. Pain [MG30-MG3Z] [11]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Baclofen and Oxycodone. Pain [MG30-MG3Z] [11]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Baclofen and Fentanyl. Sensation disturbance [MB40] [11]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Baclofen and Sufentanil. Sensation disturbance [MB40] [11]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Baclofen and Tizanidine. Tonus and reflex abnormality [MB47] [21]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Baclofen and Cetirizine. Vasomotor/allergic rhinitis [CA08] [22]
⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Baclofen 10 mg tablet 10 mg Oral Tablet Oral
Baclofen 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1084).
2 ClinicalTrials.gov (NCT01706523) Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders. U.S. National Institutes of Health.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
9 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
10 Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
11 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
12 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
13 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
14 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
15 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
16 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
17 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
18 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
19 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
20 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
21 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
22 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.